Gihan Tennekoon
Overview
Explore the profile of Gihan Tennekoon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
552
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Finkel R, Darras B, Mendell J, Day J, Kuntz N, Connolly A, et al.
J Neuromuscul Dis
. 2023 Mar;
10(3):389-404.
PMID: 36911944
Background: Spinal muscular atrophy (SMA) is a neuromuscular disorder arising from biallelic non-functional survival motor neuron 1 (SMN1) genes with variable copies of partially functional SMN2 gene. Intrathecal onasemnogene abeparvovec...
2.
Fragala-Pinkham M, Pasternak A, McDermott M, Mirek E, Glanzman A, Montes J, et al.
J Pediatr Rehabil Med
. 2021 Jul;
14(3):451-461.
PMID: 34275913
Purpose: The purpose of this study was to examine the psychometric properties of the Pediatric Evaluation of Disability Inventory-Computer Adaptive Test (PEDI-CAT) in children and youth with Spinal Muscular Atrophy...
3.
Finkel R, Finanger E, Vandenborne K, Sweeney H, Tennekoon G, Shieh P, et al.
Neuromuscul Disord
. 2021 Mar;
31(5):385-396.
PMID: 33678513
Chronic activation of NF-κB is a key driver of muscle degeneration and suppression of muscle regeneration in Duchenne muscular dystrophy. Edasalonexent (CAT-1004) is an orally-administered novel small molecule that covalently...
4.
Yildiz S, Glanzman A, Estilow T, Flickinger J, Brandsema J, Tennekoon G, et al.
Am J Phys Med Rehabil
. 2020 Mar;
99(9):789-794.
PMID: 32195737
Objective: Prevalence and characteristics of fractures and factors related to loss of ambulation after lower limb fractures were investigated. Design: Chart review included height, weight, dual-energy x-ray absorptiometry, corticosteroid use,...
5.
Rooney W, Berlow Y, Triplett W, Forbes S, Willcocks R, Wang D, et al.
Neurology
. 2020 Mar;
94(15):e1622-e1633.
PMID: 32184340
Objective: To quantify disease progression in individuals with Duchenne muscular dystrophy (DMD) using magnetic resonance biomarkers of leg muscles. Methods: MRI and magnetic resonance spectroscopy (MRS) biomarkers were acquired from...
6.
Barnard A, Willcocks R, Triplett W, Forbes S, Daniels M, Chakraborty S, et al.
Neurology
. 2020 Feb;
94(9):e897-e909.
PMID: 32024675
Objective: To investigate the potential of lower extremity magnetic resonance (MR) biomarkers to serve as endpoints in clinical trials of therapeutics for Duchenne muscular dystrophy (DMD) by characterizing the longitudinal...
7.
Mohassel P, Liewluck T, Hu Y, Ezzo D, Ogata T, Saade D, et al.
Ann Clin Transl Neurol
. 2019 Sep;
6(10):1980-1988.
PMID: 31509352
Objective: To characterize the natural history and clinical features of myopathies caused by mono-allelic, dominantly acting pathogenic variants in COL12A1. Methods: Patients with dominant COL12A1-related myopathies were characterized by history...
8.
Finanger E, Vandenborne K, Finkel R, Sweeney H, Tennekoon G, Yum S, et al.
J Neuromuscul Dis
. 2018 Nov;
6(1):43-54.
PMID: 30452422
Background: Edasalonexent is an orally administered small molecule designed to inhibit NF-κB, which is activated from infancy in Duchenne muscular dystrophy and is central to causing muscle damage and preventing...
9.
Montes J, McDermott M, Mirek E, Mazzone E, Main M, Glanzman A, et al.
PLoS One
. 2018 Jun;
13(6):e0199657.
PMID: 29944707
Individuals with spinal muscular atrophy (SMA) type 3 are able to walk but they have weakness, gait impairments and fatigue. Our primary study objective was to examine longitudinal changes in...
10.
Glanzman A, Mazzone E, Dunaway Young S, Gee R, Rose K, Mayhew A, et al.
J Neuromuscul Dis
. 2018 Jun;
5(2):159-166.
PMID: 29865090
Background: Training methodology was established to optimize reliability of outcome measures in the nusinersen clinical trials. The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND), Hammersmith Functional...